eSource Enabled Risk-Based Monitoring
In the face of increasing clinical trial costs, complexity and regulations, drug makers are under increasing pressure to save money while executing more efficient clinical trials. In an effort to enhance subject protection and clinical trial data quality, the Food and Drug Administration (FDA) issued final industry guidance in August 2013, “Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring”.